nkg2d-fc fusion protein qeq278
Generic: NKG2D-Fc Fusion Protein QEQ278
nkg2d-fc fusion protein qeq278: 1 clinical trial tracked.
nkg2d-fc fusion protein qeq278 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about nkg2d-fc fusion protein qeq278, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase I/Ib, Open-label, Multi-center, Study of QEQ278 in Patients With Advanced Solid Tumors
Primary endpoint: Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Interventionalopen30 targetStarted 2023-04Completion 2026-0112 sites · Belgium, France, Germany, Italy…Novartis Pharmaceuticals